Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors
- 7 June 2004
- journal article
- Published by Springer Nature in Oncogene
- Vol. 23 (36) , 6056-6063
- https://doi.org/10.1038/sj.onc.1207810
Abstract
We have recently demonstrated that the pyrazolopyrimidines PP1 and PP2 and the 4-anilinoquinazoline ZD6474 display a strong inhibitory activity (IC50100 nM) towards constitutively active oncogenic RET kinases. Here, we show that most oncogenic MEN2-associated RET kinase mutants are highly susceptible to PP1, PP2 and ZD6474 inhibition. In contrast, MEN2-associated swap of bulky hydrophobic leucine or methionine residues for valine 804 in the RET kinase domain causes resistance to the three compounds. Substitution of valine 804 with the small amino- acid glycine renders the RET kinase even more susceptible to inhibition (ZD6474 IC50: 20 nM) than the wild-type kinase. Our data identify valine 804 of RET as a structural determinant mediating resistance to pyrazolopyrimidines and 4-anilinoquinazolines.Keywords
This publication has 34 references indexed in Scilit:
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RETJournal of Medical Genetics, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- A RET double mutation in the germline of a kindred with FMTCExperimental and Clinical Endocrinology & Diabetes, 2000
- A Two-Hit Model for Development of Multiple Endocrine Neoplasia Type 2B by RET MutationsBiochemical and Biophysical Research Communications, 2000
- Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinomaOncogene, 1999
- Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domainOncogene, 1997
- Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase InhibitorJournal of Biological Chemistry, 1996
- Catalytic specificity of protein-tyrosine kinases is critical for selective signallingNature, 1995